The global diabetic retinopathy market was valued at $3.09 billion in 2020 and is projected to reach $10.79 billion by 2030, growing at a robust CAGR of 13.7%.

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene ...

AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, announced that the U.S. Food and Drug Administration ...

CAR T-cell therapy recommendations were expanded ... however, Regeneron Pharmaceuticals received a complete response letter ...

Background Fabry disease (FD) causes multiorgan sphingolipid accumulation, with cardiac involvement responsible for the ...